Clinical predictors of survival for patients with stage IV cancer referred to radiation oncology

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Kao, Johnny ^a   Gold, Kenneth D ^a   Zarrili, Gina ^a   Copel, Emily ^a   Silverman, Andrew J ^a   Ramsaran, Shanata S ^a   Yens, David ^b   Ryu, Samuel ^c  

^a Good Samaritan Hospital Medical Center   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE ACTIVITY; FEMALE; HIGH RISK POPULATION; HUMAN; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; ONCOLOGY; OVERALL SURVIVAL; PREDICTION; PRIMARY TUMOR; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; SURVIVAL TIME; TUMOR LOCALIZATION; VERY ELDERLY; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASMS; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RADIATION ONCOLOGY; RETROSPECTIVE STUDY; RISK; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIATION ONCOLOGY; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 84929497860     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124329     Document Type: Article

References (31)

1. Chow E, Fung K, Panzarella T, Bezjak A, Danjoux C, et al. A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys. 2002; 53: 1291-1302. PMID: 12128132
2. Lamont EB, Christakis NA. Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to". JAMA. 2003; 290: 98-104. PMID: 12837717
3. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ. 2000; 320: 469-472. PMID: 10678857
4. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ. 2003; 327: 195-198. PMID: 12881260
5. Gripp S, Mjartan S, Boelke E, Willers R. Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: reality or myth? Cancer. 2010; 116: 3251-3256. doi: 10.1002/cncr.25112 PMID: 20564632
6. Guadagnolo BA, Liao KP, Elting L, Giordano S, Buchholz TA, et al. Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol. 2013; 31: 80-87. doi: 10.1200/JCO.2012.45.0585 PMID: 23169520
7. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011; 8: 378-382. doi: 10.1038/nrclinonc.2011.44 PMID: 21423255
8. Rades D, Stalpers LJ, Veninga T, Schulte R, Hoskin PJ, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005; 23: 3366-3375. PMID: 15908648
9. Glare P Clinical predictors of survival in advanced cancer. J Support Oncol. 2005; 3: 331-339. PMID: 16218255
10. Maltoni M, Nanni O, Derni S, Innocenti MP, Fabbri L, et al. Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients. Eur J Cancer. 1994; 30A: 764-766. PMID: 7917534
11. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005; 23: 6240-6248. PMID: 16135490
12. Anderson F, Downing GM, Hill J, Casorso L, Lerch N. Palliative performance scale (PPS): a new tool. J Palliat Care. 1996; 12: 5-11. PMID: 8885562
13. Ma C, Bandukwala S, Burman D, Bryson J, Seccareccia D, et al. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer. 2010; 46: 3175-3183. doi: 10.1016/j.ejca.2010.06.126 PMID: 20674334
14. Barbot AC, Mussault P, Ingrand P, Tourani JM. Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors. J Clin Oncol. 2008; 26: 2538-2543. doi: 10.1200/JCO.2007.14.9518 PMID: 18487571
15. Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, et al. Predictive model for survival in patients with advanced cancer. J Clin Oncol. 2008; 26: 5863-5869. doi: 10.1200/JCO.2008.17.1363 PMID: 19018082
16. Christakis NA, Escarce JJ. Survival of Medicare patients after enrollment in hospice programs. N Engl J Med. 1996; 335: 172-178. PMID: 8657216
17. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med. 1988; 148: 1586-1591. PMID: 3382303
18. Glare PA, Eychmueller S, McMahon P. Diagnostic accuracy of the palliative prognostic score in hospitalized patients with advanced cancer. J Clin Oncol. 2004; 22: 4823-4828. PMID: 15570085
19. Janisch L, Mick R, Schilsky RL, Vogelzang NJ, O'Brien S, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994; 74: 1965-1973. PMID: 8082103
20. Rosenthal MA, Gebski VJ, Kefford RF, Stuart-Harris RC. Prediction of life-expectancy in hospice patients: identification of novel prognostic factors. Palliat Med 1993; 7: 199-204. PMID: 8261188
21. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008; 112: 650-658. PMID: 18072260
22. Kao J, Chen CT, Tong CC, Packer SH, Schwartz M, et al. Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial. Target Oncol 2014; 9: 145-153. doi: 10.1007/s11523-013-0280-y PMID: 23660867
23. Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013; 14: e28-37. doi: 10.1016/S1470-2045(12)70510-7 PMID: 23276369
24. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013; 31: 1384-1390. doi: 10.1200/JCO.2012.45.9651 PMID: 23460715
25. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer. 2009; 115: 3571-3580. doi: 10.1002/cncr.24412 PMID: 19536893
26. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012; 118: 2962-2970. doi: 10.1002/cncr.26611 PMID: 22020702
27. Kao J, Darakchiev B, Conboy L, Ogurek S, Sharma N, et al. Tumor Directed, Scalp Sparing Intensity Modulated Whole Brain Radiotherapy for Brain Metastases. Technol Cancer Res Treat. 2014 Nov 26 doi: 10.7785/tcrt.2012.500426
28. Grabowski CM, Unger JA, Potish RA. Factors predictive of completion of treatment and survival after palliative radiation therapy. Radiology. 1992; 184: 329-332. PMID: 1377829
29. Krishnan MS, Epstein-Peterson Z, Chen YH, Tseng YD, Wright AA, et al. Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model. Cancer. 2014; 120: 134-141. doi: 10.1002/cncr.28408 PMID: 24122413
30. Feliu J, Jimenez-Gordo AM, Madero R, Rodriguez-Aizcorbe JR, Espinosa E, et al. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst. 2011; 103: 1613-1620. doi: 10.1093/jnci/djr388 PMID: 21972226
31. Morita T, Tsunoda J, Inoue S, Chihara S. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer. 1999; 7: 128-133. PMID: 10335930